IRVINE, Calif., Nov. 10, 2011 /PRNewswire/ -- Shands Jacksonville Medical Center and Masimo (NASDAQ: MASI) today jointly announce the conversion of Shands Jacksonville Medical Center to Masimo rainbow® SET Pulse CO-Oximetry™ technology for advanced noninvasive patient monitoring capabilities. The conversion equips the acute care hospital, which also operates one of the biggest and busiest trauma centers, with the most technologically and clinically-advanced pulse oximetry technology—shown to have the best specificity (lowest rate of false alarms) and sensitivity (highest true alarm detection)—and noninvasive patient monitoring solutions that allow clinicians to measure multiple blood constituents, fluid responsiveness, respiration rate, and other physiological parameters without invasive blood sampling and time-consuming laboratory analysis.(1-2)
"Converting to Masimo rainbow® SET provides our clinicians with superior patient monitoring capabilities and advanced clinical measurements that offer more immediate access to a higher quality of clinical data at the point-of-care," said Dr. Michael Nussbaum, Chair of the University of Florida College of Medicine Department of Surgery at Shands Jacksonville. "Our evaluations of available pulse oximetry technology led us to the decision to standardize on Masimo's technology platform not only because it during motion and low perfusion, but because it also provides additional noninvasive blood, fluid and respiration capabilities that other oximeters can't—providing our clinicians with the clinical intelligence they need to deliver an exceptional level of care and safety to our patients."
Masimo rainbow® SET Pulse CO-Oximetry is a breakthrough technology platform that allows hospitals to noninvasively measure and continuously monitor blood constituents and physiological parameters that previously required invasive procedures—including: total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRaTM), in addition to the Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR). The pulse oximetry standard-of-care at leading hospitals worldwide, Masimo rainbow® SET provides immediate real-time results that enable clinicians to more rapidly assess patients and detect and treat adverse, potentially life-threatening conditions earlier.
Cynthia Gerdik, Director of Clinical Care Nursing at Shands Jacksonville, said the nursing staff relies on Masimo's ability to perform accurately under the most difficult of patient circumstances, "Masimo pulse ox technology is superb—even on patients with cold hands or our littlest pediatric 'wiggle worms', it just works. This was not the case with our prior pulse oximeter brand where it was not uncommon to get no or erroneous measurements on patients with cold extremities, poor perfusion, or even on patients who moved a lot. And, when you rely on pulse ox measurements as a vital sign for severely ill or trauma patients, accurate measurements are a must. Another indicator of Masimo's performance is the confidence our nurses have in its alarms. Today, when an alarm sounds on the Masimo oximeter, our nurses know that it's a real event that they need to immediately check. Masimo has freed us from alarm fatigue due to false alarms. We have trust in Masimo that we didn't have in our prior pulse ox solution."
Together, the University of Florida Health Science Center–Jacksonville and Shands Jacksonville form the region's premier academic health center–UF&Shands, a leader in the education of health professionals, a hub for clinical research and a unique provider of high-quality patient care in Northeast Florida. The conversion ensures that all multiparameter patient monitors, stand-alone oximeters, and sensors feature the advanced noninvasive patient monitoring capabilities of Masimo rainbow® SET—allowing clinicians to easily and painlessly obtain and continuously track vital blood and physiological data for patients in real-time, anywhere in the hospital.
(1) Barker SJ. Motion-Resistant Pulse Oximetry: A Comparison of New and Old Models. Anesth & Analg. 2002 Oct;95(4):967-72.
(2) Shah N, Estanol L. Comparison of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers. Anesthesiology 2006;105:A929.
About Shands Jacksonville Medical Center
Shands Jacksonville is a private, not-for-profit hospital affiliated with the University of Florida Health Science Center campuses in Jacksonville and Gainesville. In Jacksonville, UF&Shands employs 5,000 physicians and caregivers and provides care to over 34,000 inpatients and 600,000 outpatients annually. To learn more about Shands Jacksonville, visit www.shands.org
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that the hospital-wide conversion ensures that all Shands Jacksonville Hospital patients will be cared for using the most technologically and clinically-advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo rainbow SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our belief that SpHb detects low or falling hemoglobin levels that could be the result of internal bleeding; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.Media Contacts: Dan Leveton
Dana BanksShands Jacksonville
Masimo Corporation(904) 244-3268
email@example.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.
|SOURCE Masimo Corporation|
Copyright©2010 PR Newswire.
All rights reserved